GAITHERSBURG, Md. - Shares of Cell Therapeutic Inc. plunged 48.3 percent Monday after an FDA advisory panel voted unanimously that the Seattle-based firm's data were insufficient for an accelerated approval of Pixuvri (pixantrone) as a single-agent treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma who have received two or more prior lines of therapy. (BioWorld Today) Read More
